Management of Rare Uterine Malignant Tumors

With 16.1/100,000 new cases diagnosed annually in the EU, rare gynecologic tumors (RGT), including ovarian, fallopian, uterine, cervix, vaginal, and vulvar, represent more than 50% of all gynecologic cancers [1]. These cancers are commonly associated with a poor prognosis, and represent 25% of all gynecologic cancer deaths [2, 3]. It is often difficult to clearly define the natural history, the prognostic factors, and definitive histological diagnosis, as these tumors are so rare. Amongst these rare tumors, there are often considerable variability in patients’ age, the histological subtype, anatomical localization, and stage, making it difficult to determine optimal treatment strategies from the literature.